

HM2025-16: Phase Ib/II Trial of Epcoritamab plus Ibrutinib in Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma.

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of B-cell non-Hodgkin lymphoma - have relapsed or refractory aggressive B-cell lymphoma and received prior treatment with an anthracycline in combination with an anti-CD20 monoclonal antibody - treatment with autologous stem cell transplant (ASCT) is allowed if ≥ 100 days - capable of all selfcare and able to walk but unable to carry out any work activities; up and about more than 50% of waking hours - women of child-bearing potential and men must agree to use adequate contraception 2 weeks before starting treatment, for the duration of study participation and for 12 months after completing treatment - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- active central nervous system (CNS) involvement - active uncontrolled infection - current uncontrolled or symptomatic cardiovascular conditions - liver cirrhosis with moderate to severe liver impairment - significant lung disease - treatment with coumadin/warfarin - women who are pregnant or breastfeeding - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:

Procedure: Biospecimen Collection, Procedure: Bone Marrow Aspiration, Procedure: Bone Marrow Biopsy, Procedure: Computed Tomography, Biological: Epcoritamab, Drug: Ibrutinib, Procedure: Positron Emission Tomography

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), B-cell non-Hodgkin lymphoma, Lymphoma

More Information

Description: This phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory).

Study Contact: Marie Hu - hu000322@umn.edu

Principal Investigator: Marie Hu

Phase: PHASE1

IRB Number: STUDY00026284

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.